For a treatment that has been FDA cleared since 2008, transcranial magnetic stimulation remains oddly unfamiliar to most people. Patients often hear about it only after several medications have failed, and they frequently arrive with the impression that it involves something far more dramatic than it does.
Here is what the treatment actually is, how it works, and who tends to benefit.
The basic mechanism
TMS therapy uses a focused magnetic field to stimulate nerve cells in a specific region of the brain. An electromagnetic coil is positioned against the scalp, and it delivers brief magnetic pulses that pass painlessly through the skull and induce small electrical currents in the tissue beneath.
In depression treatment, the target is usually the left dorsolateral prefrontal cortex, an area involved in mood regulation that tends to show reduced activity in people with major depressive disorder. Repeated stimulation over a course of sessions appears to increase activity in that region and, importantly, to influence the broader networks it connects to.
The magnetic field strength is roughly comparable to that used in an MRI. The difference is focus and pulsing: TMS concentrates the field on a small area and delivers it in rapid trains rather than as a sustained field.
What a session actually involves
The first appointment is longer than the rest because it includes mapping. A clinician determines the patient’s motor threshold, which is the minimum pulse intensity needed to produce a small twitch in the thumb. This establishes the individual dose, since sensitivity varies considerably between people. The coil position for treatment is then calculated from anatomical landmarks.
Treatment sessions themselves are straightforward. The patient sits in a chair, fully awake and alert. No sedation or anesthesia is involved. The coil rests against the scalp and delivers pulses in cycles, typically a few seconds of stimulation followed by a brief pause, repeated for the length of the session.
Conventional protocols run somewhere between 19 and 37 minutes depending on the device and parameters. Newer intermittent theta burst protocols compress the same total stimulation into roughly three minutes, which has made scheduling considerably easier without sacrificing efficacy in head-to-head trials.
Patients drive themselves home afterward and return to normal activity immediately. There is no recovery period.
What it feels like
Most people describe the sensation as a tapping or knocking against the scalp. It is distinctly noticeable and, for a minority of patients, uncomfortable during the first week. The device also makes a loud clicking sound, so earplugs are standard.
Scalp discomfort and mild headache are the most common side effects, and both tend to diminish substantially after the first several sessions as tissue accommodates. Over-the-counter pain relief handles them when needed. Technicians can also adjust coil angle or step up intensity more gradually for patients who find the early sessions difficult.
What TMS does not produce is the systemic side effect profile that leads many people to abandon antidepressant medication. There is no weight gain, no sexual dysfunction, no sedation, and no cognitive dulling. For patients who have cycled through medications and stopped each one for reasons unrelated to efficacy, this difference is often the decisive factor.
The course of treatment
A standard course involves five sessions per week for four to six weeks, followed by a tapering period. Most protocols total around 36 sessions.
The daily schedule is the main practical burden. Six weeks of weekday appointments requires real logistical planning, which is why the shorter theta burst protocols have expanded access for working patients. Clinics such as Shanti TMS generally work to schedule sessions early or late in the day for this reason.
Response timing varies. Some patients notice changes within the second or third week, while others see little until week four or five. Improvement also tends to be reported by family members before the patient notices it themselves, which is a common enough pattern that clinicians often ask about it directly.
Who it is for
The primary FDA-cleared indication for transcranial magnetic stimulation is major depressive disorder in adults who have not responded adequately to antidepressant medication. Most insurers require documentation of failed trials, typically between one and four, before authorising coverage.
Clearances have expanded over time. Obsessive-compulsive disorder was added in 2018, smoking cessation in 2020, and depression with comorbid anxiety symptoms in 2021. Research continues into applications for PTSD, bipolar depression, and substance use disorders, though those uses remain investigational.
Outcome data from clinical practice has been reasonably consistent. Roughly half to sixty percent of patients in real-world registries show meaningful response, and somewhere around a third achieve remission. Those figures are notable given that the population receiving TMS has by definition already failed other treatments.
Who it is not for
The main contraindication is straightforward: any ferromagnetic metal in or near the head. This includes aneurysm clips, certain implants, cochlear devices, and metal fragments. Dental fillings and braces are generally fine, as are most implants below the neck, but the screening conversation is not a formality.
A history of seizures requires careful evaluation. Seizure is the most serious potential adverse event, and it is also extremely rare, with modern protocols reporting rates on the order of one in tens of thousands of sessions. Certain medications and conditions raise that baseline enough to warrant a different approach.
TMS is also not a crisis intervention. It takes weeks to work, which means acute safety concerns require a different level of care first.
What to ask before starting
A few questions separate well-run programmes from the rest. Who performs the motor threshold determination and how often is it rechecked? Which protocol does the clinic use, and why that one? Is a psychiatrist directly involved in oversight, or only nominally supervising? What happens if there is no response by week four? Does the program offer maintenance sessions, and how is relapse handled?
Also worth asking about is insurance navigation. Authorisation requirements are detailed, and clinics that handle the documentation well save patients a considerable amount of frustration.
Takeaway
TMS is not a miracle and it is not experimental. It is a well-studied, non-invasive treatment with a favorable side effect profile that works for a substantial minority of people who have not been helped by medication.
For patients who have concluded from repeated medication failures that nothing will work, the more accurate conclusion is usually narrower: that particular mechanism did not work. TMS operates on a different one, and that distinction is worth understanding before giving up on treatment altogether.
Adam Mulligan, a psychology graduate from the University of Hertfordshire, has a keen interest in the fields of mental health, wellness, and lifestyle.
